ArticleDrugs2000
Insulin glargine.
Article in Drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 77 citations in OpenAlex.
- Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial.Diabetes care · 2009Trial
- 'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.Diabetologia · 2021Review
- Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.The Journal of biological chemistry · 2018Article
- Light Control of Protein Solubility Through Isoelectric Point Modulation.Journal of the American Chemical Society · 2017Article
- Development of glucose-responsive 'smart' insulin systems.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- Review of Evidence for Adult Diabetic Ketoacidosis Management Protocols.Frontiers in endocrinology · 2017Review
- Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.Clinics (Sao Paulo, Brazil) · 2016Review
- Starting insulin in type 2 diabetes: real-world outcomes after the first 12 months of insulin therapy in a new zealand cohort.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2013Article
- Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.Pharmaceutical research · 2012Article
- Controlled release of modified insulin glargine from novel biodegradable injectable gels.AAPS PharmSciTech · 2012Article
- Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.Clinical medicine & research · 2008Review
- Insulin glargine in the treatment of type 1 and type 2 diabetes.Vascular health and risk management · 2006Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin glargine is an extended-action biosynthetic human insulin. It precipitates in the neutral environment of subcutaneous tissue and is thus gradually absorbed into the bloodstream. The addition of small amounts of zinc to the formulation further delays absorption. In small euglycaemic clamp studies, the onset of action of insulin glargine was shown to be later, the duration of action longer and the time-action profile flatter than that of Neutral Protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus and healthy volunteers. Four large clinical trials of up to 28 weeks' duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short-acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus. In 3 large comparative trials, insulin glargine decreased glycosylated haemoglobin and/or fasting blood glucose levels to a similar extent to that seen with NPH insulin in patients with insulin-dependent or non-insulin-dependent type 2 diabetes mellitus, either as monotherapy or in combination with oral hypoglycaemic agents. Insulin glargine appears to be well tolerated. A lower incidence of hypoglycaemia, especially at night, was reported in most trials with insulin glargine when compared with NPH insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.